- CEO
- Gerald R. McIlhargey
- Full Time Employees
- 1
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 4205 Carmel Mountain Drive McKinney TX United States of America 75070
- IPO Date
- Aug 8, 2005
- Business
- St. Joseph, Inc. (STJO) is a holding company engaged in investing activities and the pursuit of acquisitions of operating subsidiaries in the healthcare sector, including specialty medical devices, medical equipment, medical supplies, and nutrient products. The company provides FDA-approved and Medicare billable wearable medical devices through subsidiaries such as MedHab, which holds 14 patents for smart rehabilitation devices that connect to patients' smart devices for real-time monitoring by healthcare providers in compliance with FDA, Medicare, and HIPAA requirements; ORSA, which offers in-depth lab reports and testing services for medical supply clients; and other units focused on nutrient extraction, processing for hydration, energy, sleep aids, and medical care products, including programs targeting PTSD treatment for veterans. Additional offerings encompass sales management through NAOS, positioning St. Joseph as a one-stop supplier for doctors, hospitals, convalescent centers, elderly care facilities, and assisted living centers.
Founded in 1999 and headquartered in Salt Lake City, Utah, with an operational address at 4205 Carmel Mountain Drive, McKinney, Texas, the company formerly operated as Pottery Connection, Inc., before shifting focus from pottery production and oil and gas exploration to healthcare investments. It changed its name from St. Joseph Energy, Inc. to St. Joseph, Inc. in November 2003 and primarily serves U.S. markets, emphasizing rehabilitation, pain management, chronic care, and wellness monitoring.
In recent developments, St. Joseph verified its company profile with OTC Markets in August 2025, confirming its ongoing investment strategy amid a small market capitalization of approximately $1.26 million as of late 2025. The company divested its MedHab subsidiary, as announced in an OTC disclosure, streamlining operations toward core nutrient and supply segments; it continues pursuing acquisition candidates without disclosed new funding rounds, partnerships, or product launches in 2024-2025. These moves reflect a strategic emphasis on high-growth healthcare niches like remote monitoring and specialized nutrients.